Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

BiomX Ltd.

BiomX is a microbiome drug discovery company developing customized phage therapies that seek and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. We discover and validate proprietary bacterial targets and customize our natural and engineered phage compositions against these targets. The Company’s platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology. Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset, and SBI. *

 

Period Start 2017-05-15 renamed before
  Predecessor MBcure (IL)
Products Industry microbiomics
  Industry 2 phage therapy
Person Person Solomon, Jonathan (BiomX 201705 CEO before Proclara/NeuroPhage 201403 CEO before Israeli military)
     
Region Region Israel_oo
  Country Israel
  Street 7 Pinhas Sapir Street
  City 7414002 Ness Ziona
  Tel +972-72-3942377
    Address record changed: 2019-03-09
     
Basic data Employees n. a.
     
    �About Section� taken from web site of organisation on 08.03.
     
   
Record changed: 2019-03-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for BiomX Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top